1.
Local treatments for metastases of renal cell carcinoma: a systematic review
by Dabestani, Saeed, MD
The lancet oncology, 2014, Vol.15 (12), p.e549-e561
2.
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 s...
by Balar, Arjun V
The lancet oncology, 2017, Vol.18 (11), p.1483-1492
3.
Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, p...
by Powles, Thomas
The lancet oncology, 2020, Vol.21 (12), p.1563-1573
4.
Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial
by Choueiri, Toni K, Dr
The lancet oncology, 2016, Vol.17 (7), p.917-927
5.
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
by Balar, Arjun V, Dr
The Lancet (British edition), 2016, Vol.389 (10064), p.67-76
6.
Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
by Powles, Thomas
Nature medicine, 2019, Vol.25 (11), p.1706-1714
7.
Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and...
by Choueiri, Toni K
The lancet oncology, 2018, Vol.19 (4), p.451-460
8.
High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
by Yuen, Kobe C
Nature medicine, 2020, Vol.26 (5), p.693-698
9.
Interview with Thomas Powles: The use of durvalumab in urothelial cancer - the latest strides in immuno-oncology
by Powles, Thomas
Future oncology (London, England), 2017, Vol.13 (18), p.1581-1583
10.
Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
by Motzer, Robert J
Nature medicine, 2020, Vol.26 (11), p.1733-1741
11.
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
by Bellmunt, Joaquim
The lancet oncology, 2021, Vol.22 (4), p.525-537
12.
An adaptive, biomarker-directed platform study of durvalumab in combination with targeted therapies in advanced urothelial cancer
by Powles, Thomas
Nature medicine, 2021, Vol.27 (5), p.793-801
13.
Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial
by Powles, T
Nature medicine, 2021, Vol.27 (12), p.2200-2211
14.
Nivolumab plus cabozantinib versus sunitinib in first-line treatment for advanced renal cell carcinoma (CheckMate 9ER): long-term follow-up results from an open-label, randomised,...
by Motzer, Robert J
The lancet oncology, 2022, Vol.23 (7), p.888-898
15.
Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial
by Hussain, Syed A
The lancet oncology, 2022, Vol.23 (5), p.650-658
16.
Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial
by Powles, Thomas
Nature medicine, 2022, Vol.28 (1), p.144-153
17.
Lenvatinib plus everolimus or pembrolizumab versus sunitinib in advanced renal cell carcinoma: study design and rationale
by Grünwald, Viktor
Future oncology (London, England), 2019, Vol.15 (9), p.929-941
18.
Author Correction: High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade
by Yuen, Kobe C
Nature medicine, 2021, Vol.27 (3), p.560-560
19.
Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
by Powles, Thomas
Nature medicine, 2020, Vol.26 (6), p.983-983
20.
The conundrum of clinical trials in adult germ-cell tumours
by Powles, Thomas
The lancet oncology, 2013, Vol.14 (1), p.14-15
